Korea Exchange · Healthcare
Ilsung Is stock from India: price, numbers and tax
Ilsung Is (003120) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Ilsung Is at a glance
- Price
- ₩22,350.00+₩150.00 (0.68%)
- Market cap
- ₩160.07B
- Day range
- ₩22,100.00 – ₩22,600.00
- P/E
- 39.13
- Dividend yield
- 5.37%
- Volume
- 14.44K
- 1 month
- +7.19%
- 6 months
- -1.97%
- YTD
- +2.52%
- 1 year
- -9.33%
- 5 years
- +41.28%
Ilsung Is statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩64.3B | ₩69.0B | ₩78.1B | ₩61.2B | ₩42.1B |
| Gross profit | ₩27.1B | ₩27.0B | ₩34.7B | ₩27.9B | ₩16.1B |
| Operating income | −₩6.2B | −₩9.5B | −₩7.8B | ₩1.3B | −₩1.8B |
| Net income | ₩1.2B | ₩13.1B | −₩20.9B | ₩108.7B | −₩1.4B |
| Earnings per share | ₩170.00 | ₩1,920.80 | −₩2,994.34 | ₩2,906.40 | −₩178.32 |
| EBITDA | −₩2.8B | ₩14.6B | −₩18.2B | ₩145.4B | ₩1.6B |
| Total assets | ₩403.0B | ₩396.9B | ₩419.2B | ₩498.7B | ₩371.4B |
| Total debt | ₩132.2M | ₩161.8M | ₩238.1M | ₩274.4M | ₩181.1M |
| Cash and short-term investments | ₩225.9B | ₩222.3B | ₩235.4B | ₩299.9B | ₩64.1B |
| Shareholders' equity | ₩386.3B | ₩385.1B | ₩382.8B | ₩449.0B | ₩345.9B |
| Operating cash flow | ₩17.3B | −₩4.3B | −₩41.5B | −₩39.0B | ₩5.7B |
| Free cash flow | ₩15.1B | −₩16.3B | −₩49.2B | −₩101.5B | −₩6.9B |
| Capital expenditure | −₩2.1B | −₩12.1B | −₩7.7B | −₩62.5B | −₩12.6B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Whan In Pharm | 016580.KS | ₩10,180.00 | ₩188.17B |
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| JW Lifescience | 234080.KS | ₩10,940.00 | ₩169.40B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Kyongbo Pharmaceutical | 214390.KS | ₩5,500.00 | ₩131.49B |
| SAMSUNG PHARM. | 001360.KS | ₩1,376.00 | ₩129.51B |
| Jeil Pharma | 002620.KS | ₩7,550.00 | ₩115.90B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Ilsung Is from India
What Ilsung Is does
Ilsung Is Co., Ltd. is a South Korean pharmaceutical company established in 1961. The company specializes in the research, development, and manufacturing of medicines, with a historical focus on antibiotics. Ilsung Is operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Ilsung Is shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.